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1. Plans for the Coming Year 
For the coming year our overall objectives remain the same: tc answer 
key questions regarding the biochemical mechanisms responsible for the 
antihypertensive activity of novel compounds of our design. We plan to 
continue to pursue the specific aims originally proposed, and no changes are 
anticipated in our overall experimental strategy. 
2. Progress Report for Current Year 
This first year of the current project period has been a productive one 
for our program, with progress having been made towards all of our goals. 
Enzymology  
Our finding that DBM catalyzes aromatization of l-(2-aminoethyl)-1,4- 
cyclohexadiene (CHDEA) a process which proceeds via the normal DBM reductive 
monooxygenation pathway is significant, since aromatization of cyclohexadienes 
represents a well established trapping reaction diagnostic of single electron 
transfer processes. As set out in our publications, our unified mechanism for 
DBM processing postulates initial single electron transfer from substrate; 
thus, for example, we visualize that heteroatom cation radicals are initially 
formed with our N,S or Se substrates. We have determined the kinetic 
characteristics of CHDEA turnover, and unequivocally proven that the only 
product from the CHDEA/DBM reaction is 2-phenylethylamine; there is no 
evidence for any oxygenated products being formed. 1H-NMR, 2H-NMR and GC-MS 
analysis of the product from paired enzymatic reactions, carried out either in 
H2O or in 2H20, demonstrated that no deuterium incorporation into the product, 
PHS2590(Rev.1 
2-phenylethylamine, occurs during CHDEA/DBM turnover. Dideuterated CHDEA 
hydroxylation at the exocyclic methylene followed by aromatization in 
DBM/CHDEA reaction, but is consistent with initial abstraction of H from a 
established trapping reaction diagnostic of single electron transfer 
processes, these experiments provide direct support for the ability of the 
loss (or incorporation) effectively rules out any mechanism involving initial 
ring methylene. Since aromatization of cyclohexadienes represents a well 
activated copper oxygen species of DBM to carry out a single electron transfer 
process. 
(CHDEA-d2) was also prepared and examined as a substrate for DBM. The NMR and 
GC-MS analysis of the product from CHDEA-d2/DBM reaction revealed no loss of 
deuterium at the benzylic position of the product occurs. Lack of deuterium 
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We initiated a pilot evaluation of one class of compounds targeted at 
the enzyme tyrosine hydroxylase (TH), the monooxygenase which catalyzes 
hydroxylation of Tyr to dihydroxyphen'lalanine (DOPA), thus sitting two steps 
ahead of DBM in the pathway leading from the essential amino acid, Phe, to the 
neurotransmitter, NE. In recent work with the enzyme phenylalanine 
hydroxylase (PAH) we discovered that PAR readily carries out oxygenation of 4- 
pyridylalanine to the corresponding 4-pyridylalanine-N-Oxide. In the course 
of this work, we synthesized and fully characterized both various 
pyridylalanines and their corresponding N-oxides. We therefore reason that TH 
might similarly carry out conversion of 4-hydroxy-3-pyridylalanine (which 
exists as its pyridone tautomer) to the corresponding N-oxide (Both PAR and TH 
are non-heme-iron monooxygenases). This N-oxidation would generate the 
corresponding pyridone-N-oxide as the product, which is actually a hydroxamic 
acid N-oxide, an excellent ligand for iron. Thus, the product could readily 
inhibit TH by ligating to the essential Fe atom in the active site. To date, 
only weak TH inhibition has been observed with there prototypical compounds, 
and efforts will continue during the coming year. 
Syntheses of DBM-targeted compounds designed based on the Michael 
acceptor and Pummerer rearrangement strategies outlined in our proposal are 
underway. 
Cell Culture Experiments  
We have initiated these studies using the HOPAES derivative, since pilot 
experiments established that HPLC-EC can be conveniently used to monitor this 
compound, obviating the need to prepare radiolabeled material. We have now 
successfully initiated work with primary adrenal cultures. We have now 
obtained data which clearly establishes time- and concentration-dependent 
uptake of HOPAES into cells in culture, thus setting the stage for pursuing 
this important phase of our program. 
Bioas,s_49  
Our initial attention here has focused on MePAESe, both the racemate and 
the enantiomers which we separate as described o=in our original proposal. We 
have now obtained statistically significant data (n=5) showing potent 
antihypertensive activity for MePAESe in SHR. We have also demonstrated oral 
activity for MePAESe, an administration route which have not examined 
heretofore but which is of primary interest from the perspective of clinical 
potential. 
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